FN2 Earnings Intelligence
IDEXX Laboratories, Inc. financials
IDEXX Laboratories, Inc. (IDXX) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $144.5 | $112.5 | $453.9 | $288.3 | $180.1 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $3,215.4 | $3,367.3 | $3,661 | $3,897.5 | $4,303.7 | $4,708.4 | $5,121.2 |
| % Growth | 18.8% | 4.7% | 8.7% | 6.5% | 10.4% | 9.4% | 8.8% |
| Gross Profit | $1,889.4 | $2,004.3 | $2,190 | $2,378.9 | $2,659.6 | - | - |
| % Margin | 58.8% | 59.5% | 59.8% | 61.0% | 61.8% | - | - |
| EBITDA | $1,036.6 | $1,010.7 | $1,212 | $1,258.3 | $1,505.2 | - | - |
| % Margin | 32.2% | 30.0% | 33.1% | 32.3% | 35.0% | - | - |
| Net Income | $744.8 | $679.1 | $845 | $887.9 | $1,059.5 | - | - |
| % Margin | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% | - | - |
| Diluted EPS | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 | $14.65 | $16.56 |
| % Growth | 28.2% | -6.6% | 25.3% | 6.1% | 22.6% | 12.0% | 13.1% |
| Operating Cash Flow | $755.5 | $543 | $906.5 | $929 | $1,181.8 | - | - |
| CapEx | $119.5 | $148.8 | $133.6 | $120.9 | $124.7 | - | - |
| Free Cash Flow | $636 | $394.1 | $772.9 | $808.1 | $1,057.1 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $3,215.4 | $3,367.3 | $3,661 | $3,897.5 | $4,303.7 | $4,708.4 | $5,121.2 |
| Gross Profit | $1,889.4 | $2,004.3 | $2,190 | $2,378.9 | $2,659.6 | - | - |
| EBITDA | $1,036.6 | $1,010.7 | $1,212 | $1,258.3 | $1,505.2 | - | - |
| Net Income | $744.8 | $679.1 | $845 | $887.9 | $1,059.5 | - | - |
| Diluted EPS | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 | $14.65 | $16.56 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $144.5 | $112.5 | $453.9 | $288.3 | $180.1 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $775.2 | $694.4 | $622.9 | $449.8 | $374.8 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $755.5 | $543 | $906.5 | $929 | $1,181.8 |
| Capital Expenditure | $119.5 | $148.8 | $133.6 | $120.9 | $124.7 |
| Free Cash Flow | $636 | $394.1 | $772.9 | $808.1 | $1,057.1 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 18.8% | 4.7% | 8.7% | 6.5% | 10.4% |
| Gross Margin | 58.8% | 59.5% | 59.8% | 61.0% | 61.8% |
| EBITDA Margin | 32.2% | 30.0% | 33.1% | 32.3% | 35.0% |
| Net Margin | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% |
| FCF Margin | 19.8% | 11.7% | 21.1% | 20.7% | 24.6% |
| Diluted EPS Growth | 28.2% | -6.6% | 25.3% | 6.1% | 22.6% |